Physician profile
Sadiq Ali
NPI 1427342674
$2,480.39
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,338 · 2020: $1,123 · 2022: $19.31.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $521.57 | 2019-2020 | |
| Abbvie INC. | $352.57 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $176.92 | 2019 | |
| Novartis Pharmaceuticals Corporation | $174.25 | 2019-2020 | |
| Pfizer INC. | $149.31 | 2019 | |
| Mallinckrodt Enterprises LLC | $136.59 | 2019 | |
| Radius Health, INC. | $133.24 | 2019-2020 | |
| Glaxosmithkline, LLC. | $132.96 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $129.02 | 2020-2022 | |
| Ucb, INC. | $120.97 | 2019-2020 | |
| Genzyme Corporation | $105.62 | 2019-2020 | |
| Janssen Biotech, INC. | $90.31 | 2019-2020 | |
| Lilly USA, LLC | $66.30 | 2020 | |
| Horizon Therapeutics Plc | $59.72 | 2020 | |
| Hikma Pharmaceuticals USA | $34.38 | 2019-2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $26.29 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $21.36 | 2020 | |
| Celgene Corporation | $21.15 | 2019 | |
| Antares Pharma, INC. | $14.61 | 2019 | |
| Depuy Synthes Sales INC. | $13.25 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sadiq Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.